Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Protagonist Therapeutics, Inc. (NASDAQ: PTGX).

Full DD Report for PTGX

You must become a subscriber to view this report.


Recent News from (NASDAQ: PTGX)

Protagonist Therapeutics expands intellectual property portfolio
Protagonist Therapeutics (NASDAQ: PTGX ) announces that three new U.S. patents have been issued that strengthen intellectual property protection for its novel peptide clinical drug candidates PTG-200 and PTG-300. More news on: Protagonist Therapeutics, Healthcare stocks news, Read mo...
Source: SeekingAlpha
Date: September, 06 2018 08:27
Protagonist Therapeutics receives $1.45M SBIR funding for the development of PTG-300
Protagonist Therapeutics (NASDAQ: PTGX ) announces the receipt of a Phase 2 Small Business Innovation Research (SBIR) Grant from the National Heart, Lung and Blood Institute of the National Institutes of Health. More news on: Protagonist Therapeutics, Healthcare stocks news, Read mor...
Source: SeekingAlpha
Date: September, 06 2018 07:57
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300
NEWARK, Calif. , Sept. 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the receipt of a Phase 2 Small Business Innovation Research (SBIR) Grant from the National Heart, Lung and Blood Institute of the National Institutes of Health. This award, Number ...
Source: PR Newswire
Date: September, 06 2018 07:01
Protagonist Therapeutics Expands Intellectual Property Portfolio
NEWARK, Calif. , Sept. 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that three new U.S. patents have been issued that strengthen intellectual property protection for its novel peptide clinical drug candidates PTG-200 and PTG-300. Issued U.S. Patents...
Source: PR Newswire
Date: September, 06 2018 07:00
Abivax UC candidate shows positive action in mid-stage study
A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,...
Source: SeekingAlpha
Date: September, 05 2018 12:17
Your Daily Pharma Scoop: Foundation Promising, Paratek Moves Up, Ovid Down
Stocks in News: FMI, PRTK Foundation Medicine test helps predict response to Roche's Tecentriq in lung cancer patients Discussion : Foundation Medicine’s ( FMI ) announced a positive outcome of its bTMB assay. In a recent publication in Nature Medicine, a retrospective analysis...
Source: SeekingAlpha
Date: August, 08 2018 06:10
Protagonist misses by $0.06, beats on revenue
Protagonist (NASDAQ: PTGX ): Q2 EPS of -$0.41 misses by $0.06 . More news on: Protagonist Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 07 2018 17:00
Protagonist Therapeutics Reports Second Quarter 2018 Financial Results
NEWARK, Calif. , Aug. 7, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the second quarter ended June 30, 2018 . "Protagonist continues to advance well-differentiated therapeutic candidates discovered through its n...
Source: PR Newswire
Date: August, 07 2018 16:01
Today's Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Biotech stocks Protagonist Therapeutics and Intercept Pharmaceuticals were heading higher on Monday after positive developments and analyst upgrades. Protagonist soared after announcing results from the Protagonist PROPEL study and that it has sig...
Source: ACCESSWIRE IA
Date: August, 07 2018 08:00
3 Things In Biotech, August 7: Protagonist Makes A Very Unusual Reversal
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Protagonist propels forward in ulcerative colitis Company: Protagonist Therapeutics ( P...
Source: SeekingAlpha
Date: August, 07 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-089.089.069.248.9080,081
2018-05-216.006.346.415.97232,049
2018-05-186.096.006.145.92278,017
2018-05-176.385.996.515.87260,226
2018-05-166.456.456.5256.33201,765

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-128604,78317.9803Cover
2018-12-1113,00530,73942.3078Short
2018-12-109,56124,09339.6837Short
2018-12-072,68523,14311.6018Cover
2018-12-0611,93122,46653.1069Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PTGX.


About Protagonist Therapeutics, Inc. (NASDAQ: PTGX)

Logo for Protagonist Therapeutics, Inc. (NASDAQ: PTGX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $137,807,651 - 05/11/2018
  • Issue and Outstanding: 21,103,775 - 02/28/2018

 


Recent Filings from (NASDAQ: PTGX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (NASDAQ: PTGX)

Daily Technical Chart for (NASDAQ: PTGX)


Stay tuned for daily updates and more on (NASDAQ: PTGX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PTGX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PTGX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PTGX and does not buy, sell, or trade any shares of PTGX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/